Asthma, COPD Clinical Trial
Official title:
The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses, Airway Inflammation and Aspects of Airway Remodeling in Subjects With Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma (HDM)-Allergic Asthma
| Verified date | April 2023 |
| Source | Foresee Pharmaceuticals Co., Ltd. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma. The study will consist of two identical study periods of 12 treatment days each, separated by a washout period of at least 3 weeks (and no more than 7 weeks). Approximately 36 eligible subjects will be enrolled, to yield 32 evaluable subjects who will be treated with both FP-025 (400 mg BID) or matching placebo in a cross-over design from the evening of Day 1 till the morning of Day 12 (22 doses per study period in total).
| Status | Completed |
| Enrollment | 29 |
| Est. completion date | December 30, 2022 |
| Est. primary completion date | December 30, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 55 Years |
| Eligibility | Inclusion Criteria: The following criteria must be met by all subjects considered for study participation: 1. Females or males, between 18 and 55 years of age at Screening, inclusive, on the day of signing the Informed Consent Form (ICF). 2. Apart from a clinically stable asthma and HDM-allergy, subjects should be generally healthy with no history of a clinically relevant medical condition that in the opinion of the investigator might interfere with successful study conduct and no clinically relevant abnormalities on medical history, physical exam, vital signs, laboratory parameters or ECG at Screening. 3. Subject has a BMI = 18.0 kg/m2 and = 32.0 kg/m2 (and weighs =50 kg). 4. Subjects have been diagnosed with asthma cf GINA guidelines. 5. Subjects should have established allergy for HDM (serum HDM-specific IgE or positive SPT at Screening or documented within 1 year pre-screening). 6. No severe exacerbation of asthma within past 1 year requiring hospital admission and/or treatment with oral corticosteroids; no (never) intensive care admissions for asthma or intubation). 7. FEV1 should be =70% of predicted on Screening Day 2. 8. On Screening Day 2, PC20FEV1(Meth) should be <16 mg/mL if methacholine chloride is used (or adjusted by a factor of 1.2 if methacholine bromide is used). 9. Baseline blood eosinophils should be =150 cells/µL at Screening or documented within 3 months before Screening Day 1. 10. Subjects should have a documented airway late response to inhaled HDM on Screening Day 3. 11. Subjects of childbearing potential must be willing to use adequate contraception (double-barrier) or must refrain from intercourse. 12. Female subjects of non-childbearing potential must have had = 12 months of spontaneous amenorrhea (with folliclestimulating hormone [FSH] = 30 mIU/mL). Surgically sterile women are defined as those who have had a hysterectomy, bilateral ovariectomy (for 'benign' reasons), or bilateral tubal ligation. 13. All female subjects should have a negative pregnancy test at Screening and on Day -1. 14. Negative alcohol breath test on Screening Day 1 and Day -1. 15. Negative cotinine test on Screening Day 1 and Day -1. 16. Negative urine drug screen for recreational and other drugs on Screening Day 1 and Day -1. 17. Subjects are non-smokers. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to Screening Day 1. Number of years smoked x number of packs per day should be <5 pack years. 18. Subject should be willing and able to perform the lung function tests and other study-related procedures and comply with study protocol requirements. 19. Subject should provide a signed and dated informed consent. Exclusion Criteria: Subjects will be excluded if they meet any of the following criteria: 1. Subject has any active and/or chronic (physical or mental) condition requiring maintenance (pharmaco)therapy or which otherwise precludes subject from safe or adequate study participation (ineligibility will be assessed by the PI). 2. Subject has a history of cancer (exception: localized basalioma or cervix carcinoma in situ). 3. Subject had any major (nasal) surgery in the 6 months before Screening Day 1. 4. Subject is pregnant or lactating. 5. Subject is using immunotherapy that according to the PI may interfere with the study (e.g. in case of immunotherapy with HDM or when subject is in the updosing phase of any immunotherapy). 6. Subject regularly used alcohol (intake of >21 units/wk for males and >14 units/wk for females) and/or recreational drugs within the last 6 months prior to screening. 7. Subject had any respiratory (viral) infections (e.g. common cold) within 3 weeks of Screening Day 1 or on Day -1. 8. Subject is using maintenance asthma therapy or long-acting bronchodilators or any other anti-asthma or anti-allergic medications (as detailed in the protocol) other than infrequent use of SABA prn only. 9. Subject is using prohibited medications as detailed in the protocol. 10. Multi-sensitized symptomatic subjects with seasonal (pollen) allergies should be included outside of the relevant allergen season and/or should not be in frequent contact with the relevant allergen during the study. 11. Subject has any known allergic response for the medications used or known severe allergic reactions or anaphylaxis (to food/medications/insect venoms). 12. Subject participated in medical studies in the past 3 months (non-biologicals) or in the past 6 months (biologicals). 13. Subject is anticipated not to comply with study medication or other aspects of the study (at the discretion of the investigator). |
| Country | Name | City | State |
|---|---|---|---|
| Netherlands | Academic Medical Centre/University of Amsterdam, Department of Respiratory Medicine and Experiment Immunology | Amsterdam | |
| Netherlands | QPS Netherlands - Clinical Pharmacology Unit | Groningen |
| Lead Sponsor | Collaborator |
|---|---|
| Foresee Pharmaceuticals Co., Ltd. |
Netherlands,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | To determine the treatment effect (FP-025 versus placebo) on baseline parameters (i.e. Day 1 versus Day 10), through measurement methacholine challenge (PC20FEV1 (Meth)). | challenge will be discontinued if a fall in FEV1 of =20% from post-diluent baseline has been reached, or until the highest concentration has been administered. | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | To determine the treatment effect (FP-025 versus placebo) on baseline parameters (i.e. Day 1 versus Day 10) , through measurement of Fractionated nitric oxide (FeNO). | FeNO is measured from exhaled air by Niox Vero® device (Circassia, Oxford, United Kingdom) according to guidelines | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | To evaluate the safety and tolerability of multiple oral doses of FP-025 versus placebo in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Safety parameters include physical examination. | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | To evaluate the safety and tolerability of multiple oral doses of FP-025 versus placebo in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Safety parameters include clinical signs/symptoms reporting (MedDRA). | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | To evaluate the safety and tolerability of multiple oral doses of FP-025 versus placebo in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Safety parameters include Serious Adverse Events (SAEs). | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | To evaluate the safety and tolerability of multiple oral doses of FP-025 versus placebo in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Safety parameters include vital signs. | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | To evaluate the safety and tolerability of multiple oral doses of FP-025 versus placebo in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Safety parameters include lung function measurements. | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | Safety and tolerability of multiple oral doses of FP-025 versus placebo in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Safety parameters include clinical safety laboratory outcomes (blood/urine). | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | To evaluate the safety and tolerability of multiple oral doses of FP-025 versus placebo in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Safety parameters include ECG. | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | Pharmacokinetics of multiple oral doses of FP-025 following inhaled HDM-challenge in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Pharmacokinetic parameter measures of FP-025 in blood (plasma) include Cmax. | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | Pharmacokinetics of multiple oral doses of FP-025 following inhaled HDM-challenge in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Pharmacokinetic parameter measures of FP-025 in blood (plasma) include tmax. | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Other | Pharmacokinetics of multiple oral doses of FP-025 following inhaled HDM-challenge in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Pharmacokinetic parameter measures of FP-025 in blood (plasma) include AUC0-tau. | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Primary | The primary end point of this study is to determine the effect of FP-025 versus placebo on the allergen (HDM)-induced late asthmatic response (LAR) in subjects with clinically stable, mild allergic asthma and blood eosinophilia. | Late asthmatic response (LAR) is defined as FEV1 AUC3-8h; differences between FP025 and placebo | From Day 1 through End of Study Visit (EOS) (26 ± 2 days) for both Period 1 and Period 2 | |
| Secondary | Pharmacodynamic endpoints include the effect of study treatments on allergen (HDM)-induced changes in Late asthmatic response (LAR) | Late asthmatic response (LAR) expressed as max% fall in FEV1 from post-diluent 3-8 h(LAR) baseline post allergen | From Day 1 through End of Study Visit (EOS) (26 ± 2 days) for both Period 1 and Period 2 | |
| Secondary | Pharmacodynamic endpoints include the effect of study treatments on allergen (HDM)-induced changes in EAR. | Early asthmatic response (EAR) expressed as FEV1 AUC0-3h | From Day 1 through End of Study Visit (EOS) (26 ± 2 days) for both Period 1 and Period 2 | |
| Secondary | Pharmacodynamic endpoints include the effect of study treatments on allergen (HDM)-induced changes in Early asthmatic response (EAR). | Early asthmatic response (EAR) expressed as max% fall in FEV1 from post-diluent 0-3 h(EAR) baseline post allergen | From Day 1 through End of Study Visit (EOS) (26 ± 2 days) for both Period 1 and Period 2 | |
| Secondary | Pharmacodynamic endpoints include the effect of study treatments on allergen (HDM)-induced changes in joint HDM-induced airway response. | Joint HDM-induced airway response expressed as FEV1 AUC0-8h post-allergen. | From Day 1 through End of Study Visit (EOS) (26 ± 2 days) for both Period 1 and Period 2 | |
| Secondary | Pharmacodynamic endpoints include the effect of study treatments on allergen (HDM)-induced changes in airway hyper-responsiveness | Changes in allergen-induced AHR: i.e: PC20FEV1(Meth) or PC20FEV1(Hist) pre-post allergen (Day 10 versus Day12) | From Day 1 through End of Study Visit (EOS) (26 ± 2 days) for both Period 1 and Period 2 | |
| Secondary | Pharmacodynamic endpoints include the effect of study treatments on allergen (HDM)-induced changes in small airway parameters following HDM-challenge. | Small airway parameters measured by IOS during LAR and during EAR and over 0-8 h post-allergen challenge. | From Day 1 through End of Study Visit (EOS) (26 ± 2 days) for both Period 1 and Period 2 | |
| Secondary | Pharmacodynamic endpoints include the effect of study treatments on allergen (HDM)-induced changes in fractionated nitric oxide (FeNO) and blood eosinophils. | Changes in allergen-induced airway and systemic biomarkers (i.e. eosinophils (blood) and FeNO (exhaled air) (Day 10 versus Day12)(potential treatment effect). | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 | |
| Secondary | To determine the treatment effect (FP-025 versus placebo) on baseline parameters (i.e. Day 1 versus Day 10), through measurement of blood eosinophils. | Changes in blood eosinophils, FeNO and PC20FEV1(Meth) or PC20FEV1(Hist) Day 1 versus Day 10 (potential treatment effect) | From Day 1 through End of Study Visit (EOS) (26 ± 2 day) for both Period 1 and Period 2 |